Neurologic DysfunctionNCT07441434
DuraEEG - Duration of EEG and Treatment Outcomes in Critical Care
An observational study of Neurologic Dysfunction, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
The aim of this retrospective, observational, single-center study is to evaluate how electroencephalography (EEG) monitoring duration affects diagnosis and treatment in adult critical care patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neurologic Dysfunction
- How many people
- 800 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Jan 2014to 28 Feb 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will include all consecutive adult patients (i.e., ≥18 years of age) who were treated at the University Hospital Basel and/or were selected for a close monitoring on a monitoring Unit for EEG or continuous EEG between 2014 and until the end of 02/2025.
Who may be able to join
- Adult patients (i.e., patients ≥18 years of age)
- Received an EEG/continuous EEG
- Treated at the University Hospital of Basel on a suitable monitoring unit from 01.01.2014 - 28.02.2025.
Who cannot join
- Patients younger than 18 years
- Patients who did not receive suitable EEG monitoring
- Patients with documented refusal of the general consent
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Basel, Clinic for Intensive Care Medicine
Basel, Canton of Basel-City, 4031
About this study
The aim of this retrospective, observational, single-center study is to evaluate how electroencephalography (EEG) monitoring duration affects diagnosis and treatment in adult critical care patients.
Read the detailed description
Electroencephalography (EEG) is a diagnostic tool that records the brain's real-time electrical activity, helping detect or rule out causes of altered mental or neurological status, including life-threatening emergencies such as status epilepticus or encephalopathies. EEG can be performed as short "Spot-EEG" sessions or continuously over several days using continuous video EEG monitoring (CVEM). Prolonged EEG recordings can increase the detection of epileptic seizures or nonconvulsive status epilepticus, although previous studies have not shown a clear effect on patient outcomes. EEG findings guide treatment decisions, including starting, adjusting, or stopping therapies, and inform investigations and interventions in conditions such as encephalopathy or after cardiac arrest.
This retrospective, observational, single-center cohort study aims to identify the EEG duration that balances the benefits of detecting therapy-relevant events with the risks, resource requirements, and potential complications of prolonged monitoring.
The results of this study may help improve individualized patient care, optimize EEG use in intensive care, and guide treatment and monitoring strategies to achieve better outcomes for critically ill patients.
- Conditions
- Neurologic Dysfunction
- Keywords
- Electroencephalography, Intensive Care Unit
- Medical subject headings
- Neurologic Manifestations
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient demographics
Demographic information (e.g. age, sex) is collected.
Measured: 2014 - 02/2025
Acute prehospital management data
Data from acute prehospital management, as documented in emergency medical services (EMS) treatment protocols, is collected. The collected data elements are aggregated to describe the overall EMS response.
Measured: 2014 - 02/2025
Duration of intensive care unit stay
The length of intensive care unit (ICU) stay is recorded.
Measured: 2014 - 02/2025
Duration of hospital stay
The length of the total hospital stay is recorded.
Measured: 2014 - 02/2025
Discharge destination
The destination at discharge is recorded.
Measured: 2014 - 02/2025
Neurological deficits
The date(s) of onset and clinical course of neurological deficits, aggregated with additional clinical features are collected to capture the overall clinical presentation.
Measured: 2014 - 02/2025
Number of Nonconvulsive Status Epilepticus in ectroencephalogram
Electroencephalograms (EEGs) are collected to assess neurological activity and monitor for abnormalities that may affect treatment.
Measured: 2014 - 02/2025
Medical history
Patients' medical history, especially neurological and infectious disease history, is collected to provide a comprehensive overview of relevant clinical background.
Measured: 2014 - 02/2025
Disease etiology
The underlying causes of relevant diseases, particularly neurological and infectious conditions, are collected provide a comprehensive overview of relevant clinical background.
Measured: 2014 - 02/2025
Previous episodes of altered neurologic function
Information on previous episodes of altered neurological function, including their number and duration, is collected to provide a comprehensive measure of past disease burden.
Measured: 2014 - 02/2025
Imaging features
Neuroimaging features and other imaging features obtained during diagnostic work-up are aggregated to provide a comprehensive assessment of structural and functional abnormalities.
Measured: 2014 - 02/2025
Comprehensive assessment of the neurological status based on Richmond Agitation-Sedation Scale (RASS)
Neurological status during ICU stay is assessed using available data in the patient register from validated neurological assessments. These may include the Richmond Agitation-Sedation Scale (RASS), Sedation-Agitation Scale (SAS), Glasgow Coma Scale (GCS), or Intensive Care Delirium Screening Checklist (ICDSC). If multiple scores are available, they will be aggregated to provide a comprehensive assessment of neurological status. This outcome will be reported as a descriptive summary, synthesizing findings across tools, rather than as a single quantitative score. Richmond Agitation-Sedation Scale (RASS) is a 10-point validated tool (ranging from +4 to -5) used in intensive care to quickly assess a patient's level of sedation or agitation. A RASS score of 0 indicates an alert and calm patient, while positive scores represent agitation and negative scores indicate sedation.
Measured: 2014 - 02/2025
Comprehensive assessment of critical illness severity based on standardized scoring including the Acute Physiology and Chronic Health Evaluation II (APACHE II)systems
Disease severity during ICU stay is assessed using standardized scoring systems, including the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sequential Organ Failure Assessment (SOFA), depending on data availability in the patient register. The specific scoring system applied, as well as the scale and interpretation of the score, varies based on routine clinical practice and available documentation. Where multiple severity scores are available, they will be synthesized to provide a descriptive summary of overall illness severity rather than a single quantitative score. APACHE II uses 12 routine physiologic measurements, age, and chronic health status-collected within 24 hours of ICU admission-to calculate a score (0 to 71) predicting mortality risk. Higher scores correspond to higher disease severity.
Measured: 2014 - 02/2025
Charlson Comorbidity Index
The Charlson Comorbidity Index (CCI) is calculated based on pre-existing comorbidities and additional diagnoses. The CCI predicts the ten-year mortality for a patient who may have a range of comorbid conditions. It assigns weighted scores (from 0 to maximal 6) to 17 comorbid conditions (e.g., heart disease, diabetes, cancer), resulting in a total score ranging from 0 to 33, if the patient had the most severe form of each of the 17 conditions.
Measured: 2014 - 02/2025
Laboratory parameters
Routine laboratory value are collected. The specific parameters recorded may vary depending on the laboratory assessments documented in the patient register. All values will be reported using their respective units of measurement. These parameters are aggregated to support an overall clinical interpretation rather than a single numerical value. This approach reflects standard clinical practice, where multiple lab values are considered together to assess a patient's condition.
Measured: 2014 - 02/2025
Complications
Complications occurring during intensive care treatment or clinical monitoring are collected, including but not limited to community-acquired and nosocomial infections, shock, hemorrhage, ischemic events, arrhythmia, cardiopulmonary arrest, and organ failure. These events are aggregated to provide a comprehensive overview of serious adverse clinical outcomes during critical care rather than reported as isolated parameters.
Measured: 2014 - 02/2025
Glasgow Outcome Score
The Glasgow Outcome Score (GOS) is calculated based on the assessment of key clinical outcomes such as inhospital mortality, survival, survival with neurofunctional alteration, return to premorbid neurological function, and hospital readmission to determine the patient outcome.
The GOS ranges from 1 (death) to 5 (good recovery).
Measured: 2014 - 02/2025
Therapeutic intervention
Therapeutic interventions are documented, including duration, dosage, and number of medications, the number of drugs, administration of fluids (including blood products, crystalloids, enteral and parenteral nutrition, etc.), invasive procedures (such as intubation, mechanical ventilation, vasopressor use, and placement of central lines), and changes to any of these treatments, including the date of treatment adaptation.
Measured: 2014 - 02/2025
Vital signs
Vital signs are analyzed based on the data available in the patient register. The specific parameters recorded depend on the clinical documentation available.These values are aggregated to support an overall clinical assessment rather than a single numerical score. This reflects standard practice, where multiple vital signs are interpreted together to evaluate a patient's condition.
Measured: 2014 - 02/2025
Comprehensive assessment of the neurological status based on Sedation-Agitation Scale (SAS)
Neurological status during ICU stay is assessed using available data in the patient register from validated neurological assessments. These may include the Richmond Agitation-Sedation Scale (RASS), Sedation-Agitation Scale (SAS), Glasgow Coma Scale (GCS), or Intensive Care Delirium Screening Checklist (ICDSC). The specific tool used, as well as the scale of the score and meaning behind the score, depends on routine clinical practice and available documentation in the register. If multiple scores are available for a patient, they will be aggregated to provide a comprehensive assessment of neurological status. This outcome will be reported as a descriptive summary, synthesizing findings across tools, rather than as a single quantitative score. The sedation-Agitation Scale is a tool to assess both levels of sedation and agitation. In this tool scores 1-2 are for unawake patients and doesn't request use of sedative, while 3-7 are awake patients of which 5-7 are in need of Sedative use.
Measured: 2014 - 02/2025
Comprehensive assessment of the neurological status based on Glasgow Coma Scale (GCS)
Neurological status during ICU stay is assessed using available data in the patient register from validated neurological assessments. These may include the Richmond Agitation-Sedation Scale (RASS), Sedation-Agitation Scale (SAS), Glasgow Coma Scale (GCS), or Intensive Care Delirium Screening Checklist (ICDSC). The specific tool used, as well as the scale of the score and meaning behind the score, depends on routine clinical practice and available documentation in the register. The Glasgow Coma Scale (GCS) is a standardized neurological tool used to objectively measure and track a person's level of consciousness, particularly following traumatic brain injury. It assesses three components:eye opening (1-4), verbal response (1-5), motor response (1-6), where higher scores indicate better function.
Measured: 2014 - 02/2025
Comprehensive assessment of the neurological status based on Comprehensive assessment of the neurological status based on Intensive Care Delirium Screening Checklist (ICDSC)
Neurological status during ICU stay is assessed using available data in the patient register from validated neurological assessments. These may include the Richmond Agitation-Sedation Scale (RASS), Sedation-Agitation Scale (SAS), Glasgow Coma Scale (GCS), or Intensive Care Delirium Screening Checklist (ICDSC). The specific tool used, as well as the scale of the score and meaning behind the score, depends on routine clinical practice and available documentation in the register. The Intensive Care Delirium Screening Checklist (ICDSC) is an 8-item, validated tool used by ICU bedside nurses to rapidly screen for delirium in critically ill patients, including those who are intubated. It assesses behavioral, cognitive, and physiological symptoms over a 12-to-24-hour period, with a total score of indicating the presence of delirium.
Measured: 2014 - 02/2025
Comprehensive assessment of critical illness severity based on standardized scoring systems, including the Simplified Acute Physiology Score II (SAPS II)
Disease severity during ICU stay is assessed using standardized scoring systems, including the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sequential Organ Failure Assessment (SOFA), depending on data availability in the patient register. The specific scoring system applied, as well as the scale and interpretation of the score, varies based on routine clinical practice and available documentation. Where multiple severity scores are available, they will be synthesized to provide a descriptive summary of overall illness severity rather than a single quantitative score. The Simplified Acute Physiology Score II (SAPS II) is a severity-of-illness scoring system that estimates the risk of in-hospital mortality for adult ICU patients. Assessed within the first 24 hours of admission, it assigns 0-163 points based on age, admission type, chronic diseases, and 12 physiological variables
Measured: 2014 - 02/2025
Comprehensive assessment of critical illness severity based on standardized scoring systems, including the Sequential Organ Failure Assessment (SOFA)
Disease severity during ICU stay is assessed using standardized scoring systems, including the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sequential Organ Failure Assessment (SOFA), depending on data availability in the patient register. The specific scoring system applied, as well as the scale and interpretation of the score, varies based on routine clinical practice and available documentation. Where multiple severity scores are available, they will be synthesized to provide a descriptive summary of overall illness severity rather than a single quantitative score. The Sequential Organ Failure Assessment (SOFA) evaluates six organ systems (respiratory, cardiovascular, hepatic, coagulation, renal, and neurological), with scores ranging from 0 to 4 per system.
Measured: 2014 - 02/2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2026
- Study start1 Jan 2014
- Primary completion28 Feb 2025
- Study completion28 Feb 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neurologic DysfunctionStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 800 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Raoul Sutter, Prof. Dr. med., Principal investigator, University Hospital Basel, Clinic for Intensive Care Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07441434
- Sponsor's protocol ID
- 2025-00337; am25Sutter5
- Other IDs
- 2025
- Status last verified
- Feb 2026
- First submitted
- 10 Feb 2026
- Last updated
- 2 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DuraEEG - Duration of EEG and Treatment Outcomes in Critical Care
- ClinicalTrials.gov ID
- NCT07441434
- Acronym / sponsor ID
- 2025-00337; am25Sutter5
- Conditions
- Neurologic Dysfunction
- Keywords
- Electroencephalography, Intensive Care Unit
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 800 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 1 Jan 2014 (actual)
- Primary completion
- 28 Feb 2025 (actual)
- Study completion
- 28 Feb 2025 (actual)
- First posted
- 2 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this retrospective, observational, single-center study is to evaluate how electroencephalography (EEG) monitoring duration affects diagnosis and treatment in adult critical care patients.
Detailed description
Electroencephalography (EEG) is a diagnostic tool that records the brain's real-time electrical activity, helping detect or rule out causes of altered mental or neurological status, including life-threatening emergencies such as status epilepticus or encephalopathies. EEG can be performed as short "Spot-EEG" sessions or continuously over several days using continuous video EEG monitoring (CVEM). Prolonged EEG recordings can increase the detection of epileptic seizures or nonconvulsive status epilepticus, although previous studies have not shown a clear effect on patient outcomes. EEG findings guide treatment decisions, including starting, adjusting, or stopping therapies, and inform investigations and interventions in conditions such as encephalopathy or after cardiac arrest.
This retrospective, observational, single-center cohort study aims to identify the EEG duration that balances the benefits of detecting therapy-relevant events with the risks, resource requirements, and potential complications of prolonged monitoring.
The results of this study may help improve individualized patient care, optimize EEG use in intensive care, and guide treatment and monitoring strategies to achieve better outcomes for critically ill patients.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will include all consecutive adult patients (i.e., ≥18 years of age) who were treated at the University Hospital Basel and/or were selected for a close monitoring on a monitoring Unit for EEG or continuous EEG between 2014 and until the end of 02/2025.
Key inclusion criteria (3 listed)
- Adult patients (i.e., patients ≥18 years of age)
- Received an EEG/continuous EEG
- Treated at the University Hospital of Basel on a suitable monitoring unit from 01.01.2014 - 28.02.2025.
Key exclusion criteria (3 listed)
- Patients younger than 18 years
- Patients who did not receive suitable EEG monitoring
- Patients with documented refusal of the general consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Patient demographics
Time frame: 2014 - 02/2025
Demographic information (e.g. age, sex) is collected.
Acute prehospital management data
Time frame: 2014 - 02/2025
Data from acute prehospital management, as documented in emergency medical services (EMS) treatment protocols, is collected. The collected data elements are aggregated to describe the overall EMS response.
Duration of intensive care unit stay
Time frame: 2014 - 02/2025
The length of intensive care unit (ICU) stay is recorded.
Duration of hospital stay
Time frame: 2014 - 02/2025
The length of the total hospital stay is recorded.
Discharge destination
Time frame: 2014 - 02/2025
The destination at discharge is recorded.
Neurological deficits
Time frame: 2014 - 02/2025
The date(s) of onset and clinical course of neurological deficits, aggregated with additional clinical features are collected to capture the overall clinical presentation.
Number of Nonconvulsive Status Epilepticus in ectroencephalogram
Time frame: 2014 - 02/2025
Electroencephalograms (EEGs) are collected to assess neurological activity and monitor for abnormalities that may affect treatment.
Medical history
Time frame: 2014 - 02/2025
Patients' medical history, especially neurological and infectious disease history, is collected to provide a comprehensive overview of relevant clinical background.
Disease etiology
Time frame: 2014 - 02/2025
The underlying causes of relevant diseases, particularly neurological and infectious conditions, are collected provide a comprehensive overview of relevant clinical background.
Previous episodes of altered neurologic function
Time frame: 2014 - 02/2025
Information on previous episodes of altered neurological function, including their number and duration, is collected to provide a comprehensive measure of past disease burden.
Imaging features
Time frame: 2014 - 02/2025
Neuroimaging features and other imaging features obtained during diagnostic work-up are aggregated to provide a comprehensive assessment of structural and functional abnormalities.
Comprehensive assessment of the neurological status based on Richmond Agitation-Sedation Scale (RASS)
Time frame: 2014 - 02/2025
Neurological status during ICU stay is assessed using available data in the patient register from validated neurological assessments. These may include the Richmond Agitation-Sedation Scale (RASS), Sedation-Agitation Scale (SAS), Glasgow Coma Scale (GCS), or Intensive Care Delirium Screening Checklist (ICDSC). If multiple scores are available, they will be aggregated to provide a comprehensive assessment of neurological status. This outcome will be reported as a descriptive summary, synthesizing findings across tools, rather than as a single quantitative score. Richmond Agitation-Sedation Scale (RASS) is a 10-point validated tool (ranging from +4 to -5) used in intensive care to quickly assess a patient's level of sedation or agitation. A RASS score of 0 indicates an alert and calm patient, while positive scores represent agitation and negative scores indicate sedation.
Comprehensive assessment of critical illness severity based on standardized scoring including the Acute Physiology and Chronic Health Evaluation II (APACHE II)systems
Time frame: 2014 - 02/2025
Disease severity during ICU stay is assessed using standardized scoring systems, including the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sequential Organ Failure Assessment (SOFA), depending on data availability in the patient register. The specific scoring system applied, as well as the scale and interpretation of the score, varies based on routine clinical practice and available documentation. Where multiple severity scores are available, they will be synthesized to provide a descriptive summary of overall illness severity rather than a single quantitative score. APACHE II uses 12 routine physiologic measurements, age, and chronic health status-collected within 24 hours of ICU admission-to calculate a score (0 to 71) predicting mortality risk. Higher scores correspond to higher disease severity.
Charlson Comorbidity Index
Time frame: 2014 - 02/2025
The Charlson Comorbidity Index (CCI) is calculated based on pre-existing comorbidities and additional diagnoses. The CCI predicts the ten-year mortality for a patient who may have a range of comorbid conditions. It assigns weighted scores (from 0 to maximal 6) to 17 comorbid conditions (e.g., heart disease, diabetes, cancer), resulting in a total score ranging from 0 to 33, if the patient had the most severe form of each of the 17 conditions.
Laboratory parameters
Time frame: 2014 - 02/2025
Routine laboratory value are collected. The specific parameters recorded may vary depending on the laboratory assessments documented in the patient register. All values will be reported using their respective units of measurement. These parameters are aggregated to support an overall clinical interpretation rather than a single numerical value. This approach reflects standard clinical practice, where multiple lab values are considered together to assess a patient's condition.
Complications
Time frame: 2014 - 02/2025
Complications occurring during intensive care treatment or clinical monitoring are collected, including but not limited to community-acquired and nosocomial infections, shock, hemorrhage, ischemic events, arrhythmia, cardiopulmonary arrest, and organ failure. These events are aggregated to provide a comprehensive overview of serious adverse clinical outcomes during critical care rather than reported as isolated parameters.
Glasgow Outcome Score
Time frame: 2014 - 02/2025
The Glasgow Outcome Score (GOS) is calculated based on the assessment of key clinical outcomes such as inhospital mortality, survival, survival with neurofunctional alteration, return to premorbid neurological function, and hospital readmission to determine the patient outcome. The GOS ranges from 1 (death) to 5 (good recovery).
Therapeutic intervention
Time frame: 2014 - 02/2025
Therapeutic interventions are documented, including duration, dosage, and number of medications, the number of drugs, administration of fluids (including blood products, crystalloids, enteral and parenteral nutrition, etc.), invasive procedures (such as intubation, mechanical ventilation, vasopressor use, and placement of central lines), and changes to any of these treatments, including the date of treatment adaptation.
Vital signs
Time frame: 2014 - 02/2025
Vital signs are analyzed based on the data available in the patient register. The specific parameters recorded depend on the clinical documentation available.These values are aggregated to support an overall clinical assessment rather than a single numerical score. This reflects standard practice, where multiple vital signs are interpreted together to evaluate a patient's condition.
Comprehensive assessment of the neurological status based on Sedation-Agitation Scale (SAS)
Time frame: 2014 - 02/2025
Neurological status during ICU stay is assessed using available data in the patient register from validated neurological assessments. These may include the Richmond Agitation-Sedation Scale (RASS), Sedation-Agitation Scale (SAS), Glasgow Coma Scale (GCS), or Intensive Care Delirium Screening Checklist (ICDSC). The specific tool used, as well as the scale of the score and meaning behind the score, depends on routine clinical practice and available documentation in the register. If multiple scores are available for a patient, they will be aggregated to provide a comprehensive assessment of neurological status. This outcome will be reported as a descriptive summary, synthesizing findings across tools, rather than as a single quantitative score. The sedation-Agitation Scale is a tool to assess both levels of sedation and agitation. In this tool scores 1-2 are for unawake patients and doesn't request use of sedative, while 3-7 are awake patients of which 5-7 are in need of Sedative use.
Comprehensive assessment of the neurological status based on Glasgow Coma Scale (GCS)
Time frame: 2014 - 02/2025
Neurological status during ICU stay is assessed using available data in the patient register from validated neurological assessments. These may include the Richmond Agitation-Sedation Scale (RASS), Sedation-Agitation Scale (SAS), Glasgow Coma Scale (GCS), or Intensive Care Delirium Screening Checklist (ICDSC). The specific tool used, as well as the scale of the score and meaning behind the score, depends on routine clinical practice and available documentation in the register. The Glasgow Coma Scale (GCS) is a standardized neurological tool used to objectively measure and track a person's level of consciousness, particularly following traumatic brain injury. It assesses three components:eye opening (1-4), verbal response (1-5), motor response (1-6), where higher scores indicate better function.
Comprehensive assessment of the neurological status based on Comprehensive assessment of the neurological status based on Intensive Care Delirium Screening Checklist (ICDSC)
Time frame: 2014 - 02/2025
Neurological status during ICU stay is assessed using available data in the patient register from validated neurological assessments. These may include the Richmond Agitation-Sedation Scale (RASS), Sedation-Agitation Scale (SAS), Glasgow Coma Scale (GCS), or Intensive Care Delirium Screening Checklist (ICDSC). The specific tool used, as well as the scale of the score and meaning behind the score, depends on routine clinical practice and available documentation in the register. The Intensive Care Delirium Screening Checklist (ICDSC) is an 8-item, validated tool used by ICU bedside nurses to rapidly screen for delirium in critically ill patients, including those who are intubated. It assesses behavioral, cognitive, and physiological symptoms over a 12-to-24-hour period, with a total score of indicating the presence of delirium.
Comprehensive assessment of critical illness severity based on standardized scoring systems, including the Simplified Acute Physiology Score II (SAPS II)
Time frame: 2014 - 02/2025
Disease severity during ICU stay is assessed using standardized scoring systems, including the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sequential Organ Failure Assessment (SOFA), depending on data availability in the patient register. The specific scoring system applied, as well as the scale and interpretation of the score, varies based on routine clinical practice and available documentation. Where multiple severity scores are available, they will be synthesized to provide a descriptive summary of overall illness severity rather than a single quantitative score. The Simplified Acute Physiology Score II (SAPS II) is a severity-of-illness scoring system that estimates the risk of in-hospital mortality for adult ICU patients. Assessed within the first 24 hours of admission, it assigns 0-163 points based on age, admission type, chronic diseases, and 12 physiological variables
Comprehensive assessment of critical illness severity based on standardized scoring systems, including the Sequential Organ Failure Assessment (SOFA)
Time frame: 2014 - 02/2025
Disease severity during ICU stay is assessed using standardized scoring systems, including the Acute Physiology and Chronic Health Evaluation II (APACHE II), Simplified Acute Physiology Score II (SAPS II), and Sequential Organ Failure Assessment (SOFA), depending on data availability in the patient register. The specific scoring system applied, as well as the scale and interpretation of the score, varies based on routine clinical practice and available documentation. Where multiple severity scores are available, they will be synthesized to provide a descriptive summary of overall illness severity rather than a single quantitative score. The Sequential Organ Failure Assessment (SOFA) evaluates six organ systems (respiratory, cardiovascular, hepatic, coagulation, renal, and neurological), with scores ranging from 0 to 4 per system.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
Related trials for Neurologic Dysfunction
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
RecruitingObservational study
Impact of Vestibular Function on Deaf Infants' Activities of Daily Living
Vestibular Dysfunction, Hearing Loss
Not yet recruitingObservational study
Postural Control and Balance Performance in Patients With Carpal Tunnel Syndrome
Carpal Tunnel Syndrome (CTS), Postural Assessment
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Raoul Sutter, Prof. Dr. med. principal investigator
University Hospital Basel, Clinic for Intensive Care Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neurologic Dysfunction, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient demographics (time frame: 2014 - 02/2025). The study lists 24 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.